Company Cabaletta Bio, Inc.

Equities

CABA

US12674W1099

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 01:30:00 10/05/2024 am IST			5-day change	1st Jan Change
12.22 ^USD	+1.16%		-3.02%	-46.17%

22/03	HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating	MT
21/03	Cabaletta Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.

Number of employees: 102

Managers	Title	Age	Since
Steven Nichtberger CEO	Chief Executive Officer	62	01/17/01
Anup Marda DFI	Director of Finance/CFO	46	01/19/01
Heather Harte-Hall CMP	Compliance Officer	-	01/19/01
Samik Basu CTO	Chief Tech/Sci/R&D Officer	-	01/19/01
David Chang CTO	Chief Tech/Sci/R&D Officer	61	01/19/01
Gwendolyn Binder-Scholl CTO	Chief Tech/Sci/R&D Officer	49	01/19/01
Martha O'Connor HRO	Human Resources Officer	-	01/19/01
Arun Das PRN	Corporate Officer/Principal	34	01/19/01
Michael Gerard LAW	General Counsel	44	07/21/07

Members of the board	Title	Age	Since
Richard Henriques BRD	Director/Board Member	68	19/19/19
Steven Nichtberger CEO	Chief Executive Officer	62	01/17/01
Mark Simon BRD	Director/Board Member	62	01/18/01
Shawn Tomasello BRD	Director/Board Member	65	21/23/21
Scott Brun BRD	Director/Board Member	56	24/21/24
Catherine Bollard BRD	Director/Board Member	56	02/19/02

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	46,804,820	43,288,135 ( 92.49 %)	0	92.49 %

Name	Equities	%	Valuation
BlackRock Advisors LLC 7.897 %	3,809,766	7.897 %	65 M $
Jennison Associates LLC 7.096 %	3,422,984	7.096 %	58 M $
Fred Alger Management LLC (13f Subfiler) 6.897 %	3,327,132	6.897 %	57 M $
Adage Capital Partners GP LLC 6.771 %	3,266,645	6.771 %	56 M $
STATE STREET CORPORATION 5.378 %	2,594,470	5.378 %	44 M $
Vanguard Fiduciary Trust Co. 4.419 %	2,131,931	4.419 %	36 M $
Lynx1 Capital Management LP 4.375 %	2,110,401	4.375 %	36 M $
Deerfield Management Co. LP (Private Equity) 4.162 %	2,007,729	4.162 %	34 M $
Perceptive Advisors LLC 4.152 %	2,003,058	4.152 %	34 M $
Bain Capital Life Sciences LP 4.146 %	2,000,000	4.146 %	34 M $

Cabaletta Bio, Inc.

2929 Arch Street Suite 600

19104, Philadelphia

http://www.cabalettabio.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.22 USD

Average target price

34.5 USD

Spread / Average Target

+182.32%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
CABALETTA BIO, INC.	-46.17%	590M
VERTEX PHARMACEUTICALS INCORPORATED	+2.97%	108B
REGENERON PHARMACEUTICALS, INC.	+10.21%	104B
ARGENX SE	+2.18%	22.33B
BIONTECH SE	-12.77%	22.19B
GENMAB A/S	-7.05%	18.69B
WUXI APPTEC CO., LTD.	-37.64%	17.74B
BEIGENE, LTD.	-6.50%	17.64B
NEUROCRINE BIOSCIENCES, INC.	+6.00%	14.05B
SAREPTA THERAPEUTICS, INC.	+37.20%	12.51B

Bio Therapeutic Drugs